-
Thymosin Alpha-1: Why “Immune Support” Needs a Clinical Definition
Understand thymosin alpha-1 research, why disease-specific trials differ from general immune-support claims, and how to ask…
-
Tesamorelin With Ipamorelin: Two Ingredients, Separate Evidence Questions
Assess tesamorelin/ipamorelin claims without combining unrelated trial results, and learn what a formulation-specific consultation should clarify.
-
Tesamorelin and Visceral Fat: Why the Trial Population Matters
Understand tesamorelin visceral-fat research, its HIV-associated study populations, and why these findings differ from general weight-loss…
-
TB-500 and Thymosin Beta-4: Why the Name on the Study Matters
Learn why TB-500 claims need precise ingredient identity and why thymosin beta-4 experiments cannot automatically validate…
-
Sermorelin and Growth Hormone: Setting Useful Expectations for a Consultation
Explore sermorelin and growth-hormone discussions, why symptoms and biomarkers need context, and what to ask about…
-
Semax and Selank Together: What “Focus and Calm” Leaves Unanswered
Assess Semax/Selank combination claims by separating the ingredients’ research, the proposed delivery route, and the actual…
-
SS-31 and Elamipretide: Why a Rare-Disease Trial Is Not a Wellness Forecast
Learn how to interpret SS-31/elamipretide research, including disease-specific trials, controlled versus open-label results, and limits of…
-
Pinealon, PE-22-28, and Selank: Reading a Cognitive Blend Claim by Claim
Understand the different evidence behind Pinealon, PE-22-28, and Selank, and why a three-ingredient cognitive blend needs…
-
PT-141 and Bremelanotide: Matching Sexual-Desire Claims to the Evidence
Learn what bremelanotide trials studied, why sexual desire and erectile function are different concerns, and what…
-
NAD+ Injections and Infusions: A Metabolism Study Is Not a Longevity Guarantee
Understand NAD+ injection and infusion claims, what metabolite studies measure, and why delivery method and patient…